The MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research) study was the first to examine whether administration of ACEi (perindopril) or beta-blockers (bisoprolol) can reduce the cardiotoxic effects of trastuzumab in HER-2 positive early breast cancer patients. This evidence concerns the gene ERBB2 and breast carcinoma.